TRATAMIENTO SISTÉMICO DE LAS METÁSTASIS CEREBRALES Iván Márquez Rodas MD, PhD Servicio de Oncología Médica Hospital General Universitario Gregorio Marañón 11-11-2023
CONFLICTOS DE INTERÉS ● Advisory role: Amgen, Astra Zeneca, BiolineRx, BMS, Celegene, GSK, Highlight Therapeutics, Immunocore, Merck Serono, MSD, Novartis, Pierre Fabre, Regeneron, Roche, Sanofi, Sun Pharma ● Travel accommodation and congress: Amgen, BMS, GSK, Highlight Therapeutics, MSD, Novartis, Pierre Fabre, Roche, Sun Pharma ● Clinical trial participation as PI: Ab Science, Aduro, Agenus, Alkermes, Amgen, Astra Zeneca, Biontech, BMS, Genentech, GSK, Highlight Therapeutics, Idera, Incyte, Iovance, Kartos, Merck Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sairopa. ● If you find something I have missed, please e-mail me:
[email protected]
CHEMOTHERAPY Fotemustine: better penetrance to CNS 49 vs 80 days (brain)PFS 86 vs 105 days OS Mornex 2003 Mel Res
IMMUNOTHERAPY: IPILIMUMAB (10mg/kg) ASYMPTOMATIC AND NO STEROIDS SYMPTOMATIC (W/WO STEROIDS) 41% PREVIOUS RDT 48% PREVIOUS RDT Margolin 2012 Lancet Oncol
English